$MVIR News
Last published 2y ago
- 2y agoMVIRMedivir to present at the Pareto Securities Healthcare ConferencePR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir's fostrox + Lenvima confirm promise of improved outcomes in advanced liver cancer, detailed and mature data presented at ESMOPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir to present mature clinical data for fostrox + Lenvima at ESMO Conference and to host a webcast on September 16PR NewswireMedivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir to present updated clinical data for fostrox + Lenvima in HCC at ESMO Conference in SeptemberPR NewswireMedivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
- 2y agoMVIRNumber of shares and votes in Medivir AB on 28 June 2024PR NewswireMedivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR) today announces that the number of shares and votes in Medivir has changed during June 2024 as a result...
- 2y agoMVIRFostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GIPR NewswireMedivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
- 2y agoMVIRMedivir selects global CRO partner for upcoming phase 2b study in HCC with fostrox + Lenvima and initiates study feasibilityPR NewswireMedivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
- 2y agoMVIRMedivir to present at Redeye Growth DayPR NewswireMedivir AB (NASDAQ: MVIR) (STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
- 2y agoMVIRTNGXMedivir´s licensee, Tango Therapeutics, has discontinued development of its TNG348 clinical programPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir brings the Q1 webcast forward to 10 a.m. on April 30PR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir to present data for the combination of fostrox + Lenvima in HCC at ESMO GIPR NewswireMedivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical ...
- 2y agoMVIRFDA grants Medivir´s MIV-711 Rare Pediatric Disease Designation and Orphan Drug Designation for the treatment of Legg-Calvé-Perthes DiseasePR NewswireMedivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical ...
- 2y agoMVIRMedivir provides update from supportive Type C meeting with the FDA; preparations for enhanced phase 2b in HCC with fostrox + Lenvima continuePR NewswireMedivir AB (NASDAQ: MVIR) (STO: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical ...
- 2y agoMVIRMedivir's partner Vetbiolix announces positive results from Proof-of-Concept study with VBX-1000, previously known as MIV-701PR NewswireMedivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet...
- 2y agoMVIRMedivir to present at Investing in Oncology Forum on April 10PR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir 2023 Annual Report publishedPR NewswireMedivir AB (Nasdaq Stockholm: MVIR) today announces that the Annual Report for 2023 now is available at the company's website: www.medivir.com. In...
- 2y agoMVIRMedivir to present at Swiss Nordic Bio in Zürich on March 7PR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir to present at the Life Science Day in Gothenburg on March 6PR NewswireMedivir AB (NASDAQ STOCKHOLM: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir presents data that strengthens the fostrox/Lenvima combination in primary liver cancer at EASL Liver Cancer SummitPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRNumber of shares and votes in Medivir AB on 31 January 2024PR NewswireMedivir AB (NASDAQ Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during January 2024 as a result of the ...
- 2y agoMVIRMedivir to present at the Redeye Fight Cancer DayPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir invites to a conference call today on updated data at ASCO GI and the plans moving forward for fostrox in primary liver cancer (HCC)PR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir carries out a directed share issue of approx. SEK 20 millionPR NewswireMedivir AB (Nasdaq Stockholm: MVIR) ("Medivir" or the "Company"), a pharmaceutical company focused on developing innovative treatments for cancer in...
- 2y agoMVIRFostrox + Lenvima shows further improved response rates and time to progression in advanced liver cancer (HCC) at ASCO GI SymposiumPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir to present clinical pharmacokinetic data at EASL Liver Cancer Summit, further supporting the continued development of fostroxPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRTNGXMedivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical studyPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRFostrox + Lenvima demonstrates further improvement in durable clinical benefit in HCC, supporting the accelerated development planPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir have agreed with Lonza to manufacture a fostrox GMP campaign, to be tested in 2L HCC with intent to commercialize via accelerated approvalPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRMedivir's partner IGM Biosciences announces strategic pipeline prioritization to extend its cash runwayPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRIGMSMedivir to present at the Carlsquare Equity Research Investor DayPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRIGMSMedivir announces updated formulation of fostrox, critical to support planned study with accelerated approval intent in second line HCCPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRIGMSMedivir to present at the Redeye Life Science DayPR NewswireMedivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 2y agoMVIRIGMSMedivir to present at the Erik Penser Bank Company EventPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 3y agoMVIRIGMSMedivir to present clinical data at ASCO-GI with fostrox + Lenvima in HCC and shares positive response from Type D meeting with FDAPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 3y agoMVIRIGMSMedivir to report new and updated data from ongoing phase 2a HCC study as part of its Q3 report on FridayPR NewswireMedivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical...
- 3y agoMVIRIGMSNomination Committee of Medivir appointedPR NewswireMedivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May...
- 3y agoMVIRIGMSChange in Medivir's Board of DirectorsPR NewswireMedivir AB (Nasdaq: MVIR) and (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high...
- 3y agoIGMSMVIRFostrox + Lenvima continues to show promising tumor control in HCC, all patients have now dosed at least two treatment cyclesPR NewswireEarly and confirmed anti-tumor activity, 16 of 20 patients with disease control at first scan and sustained tumor control for 13 of 18 patients with >3 months follow-upDurable clinical benefit, median time to
- 3y agoIGMSMVIRMedivir to present at the Pareto Securities Healthcare ConferencePR NewswireSTOCKHOLM, Sweden , Sept. 14, 2023 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical
- 3y agoIGMSMVIRPromising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient includedPR NewswireContinued tumor control in the liver in 7 of the first 10 patients after three months of treatmentThe patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor
- 3y agoIGMSMVIRMedivir partners with world-leading liver cancer experts in new Scientific Advisory CouncilPR NewswireSTOCKHOLM, Aug. 7, 2023 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the
- 3y agoIGMSMVRBFMVIRMedivir has completed a successful pre-IND meeting with the FDAPR NewswireSTOCKHOLM, Dec. 12, 2022 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today
- 4y agoMVRBFMVIRNomination Committee of Medivir appointedPR NewswireSTOCKHOLM, Oct. 28, 2022 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting in May 2023. According to an
- 4y agoIGMSMVRBFMVIRA subgroup analysis of Medivir's phase II study of MIV-711 for osteoarthritis shows statistically significant reduction in OA painPR NewswireSTOCKHOLM, Feb. 28, 2022 /PRNewswire/ -- Medivir AB (NASDAQ:MVIR) (Stockholm: MVIR) today announces that an article entitled "Symptomatic and structural benefit of cathepsin K inhibition by MIV-711 in a subgroup with unilateral pain: post-hoc analysis o
- 5y agoIGMSMVRBFMVIRMedivir invites to a conference call on new clinical data and further studies with MIV-818PR NewswireSTOCKHOLM, Sept. 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) invites to a conference call on the supporting clinical data from the completed dose escalation section of the phase 1b study with MIV-818, presented today at the European Soc
- 5y agoIGMSMVRBFMVIRAbstract for MIV-818 phase 1b monotherapy for ESMO Congress publishedPR NewswireSTOCKHOLM, Sept. 13, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the Abstract entitled "Phase 1 study of the novel prodrug MIV-818 in patients with hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (iCCA)
- 5y agoIGMSMVRBFMVIRMedivir to present at the Wainwright Annual Global Investment ConferencePR NewswireSTOCKHOLM, Sept. 10, 2021 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR) today announces that the company will present at the virtual meeting H.C. Wainwright Annual Global Investment Conference, September 13-15. The presentation will be available
- 5y agoIGMSMVRBFMVIRMedivir receives regulatory approval from MHRA for phase 1/2a combination study with MIV-818PR NewswireSTOCKHOLM, Aug. 31, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announced that the company has received regulatory approval from the British Medicines & Healthcare products Regulatory Agency (MHRA) for its upcoming phase 1/2a combinat
- 5y agoIGMSMVRBFMVIRMedivir strengthens the business development potential of remetinostat through renegotiated multi-party agreementPR NewswireHUDDINGE, Sweden, Aug. 16, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that Medivir AB ("Medivir" or "the Company") together with the originators of remetinostat, and TetraLogic Pharmaceuticals Corporation and The Leukemia &
- 5y agoIGMSMVRBFMVIRPositive data from the remetinostat phase II study in basal cell carcinoma published in Clinical Cancer ResearchPR NewswireSTOCKHOLM, Aug. 12, 2021 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) announced today that positive data from the investigator-initiated study evaluating the effects of remetinostat in basal cell carcinoma (BCC) patients has been published in Cli